The developer of the influenza treatment Avigan says the drug's efficacy in treating COVID-19 patients has been confirmed in a clinical trial.
Fujifilm Toyama Chemical, which is part of the Fujifilm Holdings group of companies, developed the drug. In the observational study, Avigan was given to coronavirus patients with mild symptoms.